In fact, the activation of pulmonary ACE2 with recombinant ACE2 has been proposed as a therapeutic strategy for both PAH [161] to counteract the pro-oxidant, proinflammatory, and vasoconstrictor effect of the RAAS [47]. The gene discussed is ACE2; the disease is pulmonary arterial hypertension.